vida: extract claims from 2026-05-05-statnews-true-risk-eating-disorders-glp1-april2026

- Source: inbox/queue/2026-05-05-statnews-true-risk-eating-disorders-glp1-april2026.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap.md

@@ -31,3 +31,10 @@ Systematic review characterizes current evidence state as 'low-to-moderate confi
 **Source:** NPR investigation, absence of cohort data
 
 Article provides no quantitative incidence data, only qualitative expert opinion. Curator notes: 'The article is entirely qualitative/expert opinion—no cohort data.' This confirms that the evidence gap is not just about causality but about basic epidemiological measurement—we don't have population-level data on eating disorder incidence in GLP-1 users.
+
+
+## Supporting Evidence
+
+**Source:** STAT News, April 27, 2026
+
+STAT News explicitly states 'actual research on this topic is scant' in April 2026 investigative feature. The article's framing around 'true risk' indicates ongoing debate about causality versus population selection. The ISPOR analysis provides incidence data but lacks control group, leaving the causal question unresolved.

domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md

@@ -52,3 +52,10 @@ FDA adverse event analysis found 'greater risk of abuse among patients taking se
 **Source:** ISPOR study via Timmerman Report, November 2025
 
 ISPOR study of 60,000+ GLP-1 users found 1.275% cumulative eating disorder incidence (mainly anorexia nervosa), with prior mental health conditions doubling risk. This confirms the pharmacovigilance signal is detectable in large-scale observational data and identifies behavioral substrate as primary risk stratifier.
+
+
+## Extending Evidence
+
+**Source:** STAT News, April 27, 2026; ISPOR real-world analysis
+
+ISPOR real-world analysis of 60,000+ GLP-1 users found 1.28% diagnosed with eating disorder within two years. This is total incidence in GLP-1 user population without control group comparison. STAT News characterizes the evidence base as 'scant' and quotes expert assessment that 'physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave.' The 1.28% rate, if applied to 1-in-8 Americans taking GLP-1s, projects to 420,000+ people developing eating disorders.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.m
 scope: structural
 sourcer: NEDA/ANAD
 supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
-related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population"]
 ---
 
 # GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
@@ -66,3 +66,10 @@ FDA label for oral Wegovy contains NO eating disorder warning or screening requi
 **Source:** NPR, Dr. Samantha DeCaro and Dr. Kim Dennis interviews
 
 Dr. DeCaro and Dr. Dennis provide clinical expert consensus that screening protocols exist (SCOFF questionnaire plus history plus behavioral assessment) but are not implemented due to structural barriers, not knowledge gaps. The article notes 'easy online access with little screening creates vulnerability in susceptible populations,' confirming that the gap is operational infrastructure, not clinical uncertainty about what to screen for.
+
+
+## Supporting Evidence
+
+**Source:** STAT News, April 27, 2026
+
+Expert assessment that healthcare system is 'unprepared for this coming wave' of eating disorder cases suggests infrastructure gap extends beyond screening protocols to treatment capacity. The 420,000 person projection (1.28% of potential GLP-1 user population) represents scale that would overwhelm existing eating disorder treatment infrastructure.

inbox/archive/health/2026-05-05-statnews-true-risk-eating-disorders-glp1-april2026.md

@@ -7,10 +7,13 @@ date: 2026-04-27
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, eating-disorders, semaglutide, incidence, regulatory-gap, screening, evidence-gap, pharmacovigilance]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content